← Patent-cliff monitor small molecule LEQSELVI DEURUXOLITINIB PHOSPHATE
Loss of exclusivity October 2044 latest FDA-listed patent expiry
Company SUN PHARMACEUTICAL INDUSTRIES INC
Drug detail Brand name LEQSELVI Active ingredient DEURUXOLITINIB PHOSPHATE Strength EQ 8MG BASE Dosage form TABLET Route ORAL Modality Small molecule FDA approval July 2024 Marketing status RX
Listed patents Patent Expires Type 12364699 October 2044 use U-3976 12247034 May 2044 substance, product 12285432 August 2042 use U-3976 11919907 May 2041 product 10561659 May 2037 use U-3976 12076323 May 2037 use U-3976
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.